Clarity Pharmaceuticals Ltd Asset Resilience Ratio

Latest as of December 2025: 73.99%

Clarity Pharmaceuticals Ltd asset resilience ratio. Clarity Pharmaceuticals Ltd (CU6) has an Asset Resilience Ratio of 73.99% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Clarity Pharmaceuticals Ltd to measure how many days the company can operate on defensive assets alone.

Liquid Assets

AU$189.17 Million
≈ $133.85 Million USD Cash + Short-term Investments

Total Assets

AU$255.67 Million
≈ $180.90 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Clarity Pharmaceuticals Ltd (2019–2025)

Asset resilience ratio of Clarity Pharmaceuticals Ltd from 2019 to 2025. This chart shows how Clarity Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Read Clarity Pharmaceuticals Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Clarity Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Clarity Pharmaceuticals Ltd total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$33.37 Million 13.05%
Short-term Investments AU$155.80 Million 60.94%
Total Liquid Assets AU$189.17 Million 73.99%

Asset Resilience Insights

  • Very High Liquidity: Clarity Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 73.99% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Clarity Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Clarity Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

Clarity Pharmaceuticals Ltd Asset Resilience Ratio by Year (2019–2025)

Clarity Pharmaceuticals Ltd asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Clarity Pharmaceuticals Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 65.08% AU$65.84 Million
≈ $46.59 Million
AU$101.17 Million
≈ $71.59 Million
-2.05pp
2024-06-30 67.13% AU$103.80 Million
≈ $73.45 Million
AU$154.63 Million
≈ $109.41 Million
-9.65pp
2023-06-30 76.78% AU$59.04 Million
≈ $41.77 Million
AU$76.90 Million
≈ $54.41 Million
+14.67pp
2022-06-30 62.11% AU$62.00 Million
≈ $43.87 Million
AU$99.82 Million
≈ $70.63 Million
+15.68pp
2021-06-30 46.43% AU$10.50 Million
≈ $7.43 Million
AU$22.61 Million
≈ $16.00 Million
+35.46pp
2020-06-30 10.97% AU$1.00 Million
≈ $707.56K
AU$9.12 Million
≈ $6.45 Million
-32.67pp
2019-06-30 43.65% AU$4.52 Million
≈ $3.20 Million
AU$10.36 Million
≈ $7.33 Million
--
pp = percentage points

About Clarity Pharmaceuticals Ltd

AU:CU6 Australia Biotechnology
Market Cap
$364.29 Million
AU$514.85 Million AUD
Market Cap Rank
#13615 Global
#356 in Australia
Share Price
AU$1.38
Change (1 day)
-6.12%
52-Week Range
AU$1.38 - AU$4.62
All Time High
AU$8.79
About

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic rad… Read more